Abstract:Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous group of mostly incurable hematologic malignancies driven by transformed stem cells (leukemic stem cells, LSC) endowed with enhanced self-renewal capacity and blocked myeloid differentiation. Insights into pathways of LSC maintenance will provide key targets for curative therapies. We have previously shown that chaperone-mediated autophagy (CMA) is essential for metabolic adaptation in HSC to regenerative stress (Dong et al., Nature 2021). To test the relevance of CMA in LSC, we developed new mouse models of AML with concomitant CMA deficiency through conditionally deleting (Vav-iCre driven) Lysosome-associated membrane protein 2 (Lamp2a, L2A) which is specific and rate-limiting for this autophagy pathway. We characterized self-renewal and myeloid differentiation potential of leukemia cells upon L2A deletion by gold-standard serial ex vivo colony assays and in vivo bone marrow transplantation assays. Our data thus far have revealed that CMA blockade causes compromised ex vivo self-renewal of LSC and significantly prolongs survival of recipients upon adoptive cell transfer compared to L2AWT controls, consistent with compromised LSC maintenance. Moreover, CMA deficient LSC presented with significantly increased myeloid differentiation compared to CMA competent LSC, suggesting that CMA impacts molecular pathways that favor self-renewal over differentiation commitment. We are currently building precise humanized models and employ degron-mediated ablation of L2A to test the consequences of CMA ablation in human AML. If successful, our study will provide exciting preclinical rationales for the testing of CMA inhibitors for eradication of LSC, particularly alongside current mainstay therapies, as a novel and potential curative option for patients with myeloid malignancies. Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous group of mostly incurable hematologic malignancies driven by transformed stem cells (leukemic stem cells, LSC) endowed with enhanced self-renewal capacity and blocked myeloid differentiation. Insights into pathways of LSC maintenance will provide key targets for curative therapies. We have previously shown that chaperone-mediated autophagy (CMA) is essential for metabolic adaptation in HSC to regenerative stress (Dong et al., Nature 2021). To test the relevance of CMA in LSC, we developed new mouse models of AML with concomitant CMA deficiency through conditionally deleting (Vav-iCre driven) Lysosome-associated membrane protein 2 (Lamp2a, L2A) which is specific and rate-limiting for this autophagy pathway. We characterized self-renewal and myeloid differentiation potential of leukemia cells upon L2A deletion by gold-standard serial ex vivo colony assays and in vivo bone marrow transplantation assays. Our data thus far have revealed that CMA blockade causes compromised ex vivo self-renewal of LSC and significantly prolongs survival of recipients upon adoptive cell transfer compared to L2AWT controls, consistent with compromised LSC maintenance. Moreover, CMA deficient LSC presented with significantly increased myeloid differentiation compared to CMA competent LSC, suggesting that CMA impacts molecular pathways that favor self-renewal over differentiation commitment. We are currently building precise humanized models and employ degron-mediated ablation of L2A to test the consequences of CMA ablation in human AML. If successful, our study will provide exciting preclinical rationales for the testing of CMA inhibitors for eradication of LSC, particularly alongside current mainstay therapies, as a novel and potential curative option for patients with myeloid malignancies.

Abstract 1703: SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping and accessibility

Abstract 6051: Discovery of oral SMARCA2 degraders for the treatment of SMARCA4 mutant tumors

Abstract 419: The development of BRPF1 degraders as a potential treatment for acute myeloid leukemia

Abstract 1599: SMARCA4 regulates tumor resistance to anti-tumor immune response

Abstract 3879: Development of Potent, Highly Selective and Efficacious SMARCA2 Degraders

Abstract 4506: Discovery of potent, highly selective and orally efficacious SMARCA2 degraders

Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2

Abstract 1687: Targeted degradation of MECOM in high-risk acute myeloid leukemia reveals a novel repressive function that is amenable to therapeutic small-molecule rewiring

Abstract 6567: Affinity and cooperativity modulate ternary complex formation to drive degradation of SMARCA2

Abstract 3304: Modulation of enhancer accessibility by SMARCA2 PROTACs synergize with TEAD inhibitors to suppress growth of SMARCA4 mutant lung cancers

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer

Abstract 3229: IACS-16559, a CBP/P300 bromodomain inhibitor for the treatment of specific AML subsets

Abstract 1723: Targeting SMARCA1 in rhabdomyosarcoma: Potential therapeutic implications

Abstract 5795: Potent and selective degradation of KAT2A and KAT2B induces profound cell state changes and inhibits growth of AML, SCLC and NEPC model systems

Abstract A19: Targeting epigenetic regulators to override cellular identity programs and induce therapeutic differentiation in MLL-rearranged acute myeloid leukemia

3118 – CHAPERONE-MEDIATED AUTOPHAGY MAINTAINS LEUKEMIC STEM CELLS

Abstract 5592: HMGA1 modulates chromatin state and transcriptional networks involved in plasticity in refractory myeloid leukemia

Abstract 5628: Aberrant 3'UTR processing regulates a tumor suppressor network in AML

Abstract 5851: Dysregulated RNA splicing promotes AML quiescence and chemoresistance

Abstract 6869: Paired single-cell B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cell immunity in acute myeloid leukemia

The splicing factor RBM17 drives leukemic stem cell maintenance by evading nonsense-mediated decay of pro-leukemic factors